ProMetic Life Sciences Inc. Expands Sites For PBI-1402 And Initiates PBI-1393 Clinical Trials

MONTREAL, CANADA -- (MARKET WIRE) -- September 13, 2006 -- Prometic Life Sciences Inc. (TSX: PLI) ("ProMetic") is pleased to announce that the Board of Directors has approved plans to expand its PBI-1402 phase Ib/II clinical trial to multiple sites in Canada and Europe. PBI-1402 is an orally active drug targeting anemia. The Company will also initiate PBI-1393 clinical trials for advanced cervical cancer.

Back to news